{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Validated immunoassays were used to test for the presence of anti-denosumab antibodies throughout the study.","groups":[{"description":"Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg dose on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.","id":"OG000","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"Participants who received at least 1 dose of denosumab and had at least 1 anti-denosumab antibody sample.","reportingStatus":"POSTED","timeFrame":"From enrollment until the data cut-off date of April 7 2008; a maximum time of 18 months.","title":"Number of Participants With Anti-Denosumab Antibodies","type":"SECONDARY","unitOfMeasure":"participants"}